Logo

Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19

Share this

Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19

Shots:

  • The companies collaborated to initiate a P-III trial to evaluate the safety & efficacy of INO-4800 (2.0mg- two-dose regimen- given at a gap of 1 mos.) in healthy men & non-pregnant women aged ≥18yrs. with COVID 19 across Latin American & Asia. The study expected to commence in summer across the globe
  • The 1EPs of the trial will be virologically confirmed COVID-19 disease. The P-II data showed that the therapy was well-tolerated & immunogenic in all tested age groups
  • Under the expanded collaboration- Advaccine get rights to additional Asian countries outside of Greater China

  | Ref: PR Newswire | Image: Inovio

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions